Prices delayed by at least 15 minutes | Print


Neurocrine Biosciences (NBIX)

Common Shares
Sell: $139.87|Buy: $150|Change: 3.20 (-2.24%)

This share can be held in a Dealing accountISALifetime ISAJISASIPP

Company profile

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.

Address

12780 El Camino Real
San Diego
CA
USA
92130


Telephone

+1 858 6177600


Sector 

Healthcare


Previous key dates

NameKey Date
Neurocrine Biosciences Inc Annual General Meeting for 20242024-05-17T10:30:00
Neurocrine Biosciences Inc First Quarter Earnings Conference Call for 20242024-05-01T08:00:00
Neurocrine Biosciences Inc First Quarter Earnings Results for 20242024-05-01T07:00:00
Neurocrine Biosciences Inc Stifel Virtual CNS Days Conference 20242024-03-19T14:00:00
Neurocrine Biosciences Inc UBS Virtual CNS Day Conference 20242024-03-18T12:00:00
the Barclays 26th Annual Global Healthcare Conference2024-03-13T10:15:00
Matt Abernethy and Kyle Gano will present at the Leerink Partners Global Biopharma Conference2024-03-12T08:40:00
the TD Cowen 44th Annual Healthcare Conference2024-03-05T11:10:00
Neurocrine Biosciences Inc Annual Report for 20232024-02-09T00:00:00
Neurocrine Biosciences Inc Fourth Quarter Earnings Conference Call for 20232024-02-07T08:00:00
Neurocrine Biosciences Inc Fourth Quarter Earnings Results for 20232024-02-07T07:00:00
Neurocrine Biosciences Inc Third Quarter Earnings Conference Call for 20232023-10-31T08:00:00
Neurocrine Biosciences Inc Third Quarter Earnings Results for 20232023-10-31T07:00:00
Neurocrine Biosciences Inc Second Quarter Earnings Conference Call for 20232023-08-01T08:00:00
Neurocrine Biosciences Inc Second Quarter Earnings Results for 20232023-08-01T07:00:00
Neurocrine Biosciences Inc Annual General Meeting for 20232023-05-17T10:30:00
Neurocrine Biosciences Inc First Quarter Earnings Conference Call for 20232023-05-03T08:00:00
Neurocrine Biosciences Inc First Quarter Earnings Results for 20232023-05-03T07:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2024 AJ Bell. All rights reserved.